All In Biotech

Drug Trial Radar · NCT03702855

Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions

An Open Label, Balanced, Randomized, Two-treatment, Four-period, Two-sequence, Single Dose, Crossover, Fully Replicated Oral Bioequivalence Study of Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited, India Comparing With XENAZINE® (Tetrabenazine) Tablets 25 mg of Lundbeck Inc., USA in Healthy, Adult, Human Subjects Under Fed Conditions

Last checked: Nov 20, 2026Latest source record: Oct 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Dec 2015

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Sponsor type
Industry
First posted
Oct 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, four-period, two-treatment, two-sequence, balanced, single dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fed conditions.

Conditions

  • Healthy

Interventions

  • Tetrabenazine Tablets 25 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under curveTime frame: Pre-dose (within 1 hour prior to dosing), 0.33, 0.67, 1.00, 1.33, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 24.00 hours post dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Accutest Research Laboratories (I) Pvt. Ltd.

    Navi Mumbai, Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.